Overview

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-03-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

Phase:

PHASE2

Details

Lead Sponsor:

C4 Therapeutics, Inc.

Treatments:

Dexamethasone